Onyema Ogbuagu, MBBCH, FACP, FIDSA

home / authors / onyema-ogbuagu-mbbch-facp-fidsa

Ogbuagu is an associate professor of medicine and director of the HIV clinical trials program of the Yale AIDS Program, section of infectious diseases at the Yale School of Medicine in New Haven, Connecticut.

Articles

Phase II Study Shows Efficacy of 6-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV

Phase II Study Shows Efficacy of 6-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIV

Sophia Abene;Onyema Ogbuagu, MBBCH, FACP, FIDSA
March 18th 2025

Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.

Read More

Long-Acting Lenacapavir Shows Efficacy in Heavily Treatment-Experienced Patients

Long-Acting Lenacapavir Shows Efficacy in Heavily Treatment-Experienced Patients

Sophia Abene;Onyema Ogbuagu, MBBCH, FACP, FIDSA
November 11th 2024

Findings from the CAPELLA study reveal virologic suppression and a safety profile for multidrug-resistant HIV-1.

Read More

Lenacapavir Reduces HIV Infections by 96%, Demonstrates Superiority Over Another HIV Prophylactic

Lenacapavir Reduces HIV Infections by 96%, Demonstrates Superiority Over Another HIV Prophylactic

John Parkinson;Onyema Ogbuagu, MBBCH, FACP, FIDSA
September 12th 2024

Gilead’s HIV-1 capsid inhibitor, which is a twice-yearly injection, was more effective than a daily Truvada pill in a phase 3 trial.

Read More

Examining a Newer Therapy for Heavily Treated HIV Patients

Examining a Newer Therapy for Heavily Treated HIV Patients

John Parkinson;Onyema Ogbuagu, MBBCH, FACP, FIDSA
March 7th 2024

The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.

Read More

HIV Vaccine Progress in the Context of a Decades-Long Struggle: What Are the Challenges?

HIV Vaccine Progress in the Context of a Decades-Long Struggle: What Are the Challenges?

Jessica Tuan, MD, MS, AAHIVS;Onyema Ogbuagu, MBBCH, FACP, FIDSA
August 17th 2023

Read More

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
New Insights Into Fungal Infections, Including Resistance, Mortality, and Environmental Risks
Published: April 29th 2025 | Updated: May 5th 2025
New Insights Into Fungal Infections, Including Resistance, Mortality, and Environmental Risks
Pneumonia Antibiotic Cures Lyme Disease at Doses 100 Times Lower Than Standard Treatment
Published: April 29th 2025 | Updated: May 5th 2025
Pneumonia Antibiotic Cures Lyme Disease at Doses 100 Times Lower Than Standard Treatment
As US Measles Cases Rise to 884, the European Centre for Disease Prevention and Control Reports Over 35,000 Infections in 2024
Published: April 29th 2025 | Updated: May 5th 2025
As US Measles Cases Rise to 884, the European Centre for Disease Prevention and Control Reports Over 35,000 Infections in 2024
Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders
Published: April 28th 2025 | Updated: May 5th 2025
Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders
Novavax vs mRNA Vaccines: Understanding Vaccine Reactogenicity
Published: April 28th 2025 | Updated: May 5th 2025
Novavax vs mRNA Vaccines: Understanding Vaccine Reactogenicity
© 2025 MJH Life Sciences

All rights reserved.